UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 481 - 495 of 671

<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

[Anticholinergic Drugs in Overactive Bladder.] - Abstract
Wednesday, 23 January 2008
Maternité régionale A. Pinard, 10, rue du Docteur Heydenreich, CS 74213, 54042 Nancy cedex, France
read more

Evolution of Transdermal Oxybutynin in the Treatment of Overactive Bladder - Abstract
Monday, 21 January 2008
Department of Urology, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.
read more

Efficacy of Tolterodine in Relation to Different Urodynamic Findings of Detrusor Overactivity - Abstract
Friday, 18 January 2008
Urogynaecology Unit, University of Insubria, Del Ponte Hospital, Varese, Italy
read more

Satisfaction with Tolterodine: Assessing Symptom-Specific Patient-Reported Goal Achievement in the Treatment of Overactive Bladder in Female Patients (STARGATE study) - Abstract
Wednesday, 16 January 2008
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
read more

Pediatric Overactive Bladder Syndrome: Pathophysiology and Management - Abstract
Monday, 14 January 2008
Section of Pediatric Urology, New York Medical College, Valhalla, New York, USA
read more

Transdermal Oxybutynin in the Treatment of Overactive Bladder - Abstract
Monday, 31 December 2007
Department of Gynecology, Section of Urogynecology and Reconstructive Pelvic Surgery, Cleveland Clinic, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
read more

Urinary Stress Incontinence and Overactive Bladder Symptoms in Older Women - Abstract
Monday, 31 December 2007
School of Health Sciences, University of Newcastle, Callaghan NSW, Australia
read more

Treatment of Overactive Bladder in the Aging Population: Focus on Darifenacin - Abstract
Friday, 28 December 2007
Department of Urogynaecology, Birmingham Women's Hospital, Birmingham, UK
read more

Pharmacologic Management of Overactive Bladder - Abstract
Wednesday, 26 December 2007
St. John's University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, 8000 Utopia Parkway, St. Albert Hall, Room 114, Queens, NY 11439-0001, USA
read more

Urinary Incontinence at Orgasm: Relation to Detrusor Overactivity and Treatment Efficacy - Abstract
Monday, 17 December 2007
Department of Obstetrics and Gynecology, University of Insubria, Del Ponte Hospital, Varese, Italy
read more

Solifenacin Treatment for Overactive Bladder in Hispanic Patients: Patient-Reported Symptom Bother and Quality of Life Outcomes from the VESIcare((R)) Open-Label Trial - Abstract
Friday, 14 December 2007
Internal Medicine Associates of Atlanta, Atlanta, GA, USA
read more

Therapeutic Receptor Targets for Lower Urinary Tract Dysfunction - Abstract
Thursday, 13 December 2007
Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA, 15213, USA
read more

Tolterodine does not Affect Memory Assessed by Passive-Avoidance Response Test in Mice - Abstract
Wednesday, 12 December 2007
Pfizer Global Research and Development, Groton, CT, United States
read more

Neuromodulation for the Treatment of Urinary Incontinenc - Abstract
Tuesday, 11 December 2007
Department of Obstetrics, Gynecology and Women's Health, Division of Urogynecology and Reconstructive Pelvic Surgery, Saint Louis University School of Medicine, USA
read more

The Impact of Tension-Free Vaginal Tape on Overactive Bladder Symptoms in Women With Stress Urinary Incontinence: Significance of Detrusor Overactivity - Abstract
Monday, 10 December 2007
Departments of Urology, Cheil General Hospital, Kwandong University College of Medicine, Seoul Korea
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder